Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Retained Earnings (2016 - 2025)

Viking Therapeutics' Retained Earnings history spans 12 years, with the latest figure at -$847.5 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 73.71% year-over-year to -$847.5 million; the TTM value through Dec 2025 reached -$847.5 million, down 73.71%, while the annual FY2025 figure was -$847.5 million, 73.71% down from the prior year.
  • Retained Earnings for Q4 2025 was -$847.5 million at Viking Therapeutics, down from -$689.9 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$182.2 million in Q1 2021 and bottomed at -$847.5 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$342.1 million (2023), against an average of -$384.6 million.
  • The largest annual shift saw Retained Earnings dropped 28.06% in 2024 before it tumbled 73.71% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$223.2 million in 2021, then crashed by 30.86% to -$292.0 million in 2022, then dropped by 29.41% to -$377.9 million in 2023, then fell by 29.1% to -$487.9 million in 2024, then plummeted by 73.71% to -$847.5 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Retained Earnings are -$847.5 million (Q4 2025), -$689.9 million (Q3 2025), and -$599.1 million (Q2 2025).